Kiper Nelson, MD
Ophthalmology · Hattiesburg, MSNPI 1548263312
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $229,733 of the $233,910 with a category attached, or 98.2%. Rxsight Inc accounts for 95.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $158,155 and has fallen 91.2% since, to $13,930 in 2025. Among ophthalmology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 141 payments — averaging $1658.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$224K
- Bausch & Lomb Americas Inc.$6K
- Alcon$1K
- Glaukos Corporation$875
- AbbVie$714
- Johnson & Johnson Surgical Vision, Inc.$197
- plus $606 from 9 others
Across 1 payment — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$5K
What the payments were for
- Consulting fees$229,73398%
- Speaking & faculty fees$260%
- Food & beverage$4,1512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 30 | $224,205 |
| Bausch & Lomb Americas Inc. | 7 | $6,209 |
| Alcon | 32 | $1,104 |
| Glaukos Corporation | 13 | $875 |
| AbbVie(2 entities) | 28 | $714 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $197 |
| NEW World Medical,inc. | 3 | $152 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $148 |
| Carl Zeiss Meditec, Inc. | 2 | $106 |
| Ivantis, Inc | 3 | $47 |
| Aerie Pharmaceuticals, Inc. | 3 | $45 |
| Sun Pharmaceutical Industries Inc. | 2 | $37 |
| Nova Eye, Inc. | 1 | $31 |
| Sight Sciences, Inc. | 1 | $27 |
| Omeros Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$157,937
- RXSIGHT CONTACT LENS$66,058
- RXSIGHT INJECTOR CARTRIDGE$66,058
- RXSIGHT INJECTOR HANDPIECE$66,058
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$66,058
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$41,092
- LIGHT ADJUSTABLE LENS (LAL)$24,967
- iDoseTR$287
- AcrySof$230
- Photrexa$140
- PanOptix$129
- iDose$115
How this compares
$233,910 in reported general payments places this provider in the 95th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 88 | $58,420 |
| XiidraLifitegrast | 15 | $13,819 |
| Prednisolone Acetate | 212 | $12,567 |
| Latanoprost | 1,114 | $8,822 |
| LumiganBimatoprost | 13 | $7,347 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 327 | $5,728 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $5,011 |
| Cyclosporine | 25 | $4,408 |
| Alphagan PBrimonidine Tartrate | 19 | $4,382 |
| Timolol Maleate | 267 | $2,473 |
| Loteprednol Etabonate | 13 | $2,342 |
| Brimonidine Tartrate | 141 | $2,120 |
| Doxycycline Monohydrate | 81 | $1,969 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 26 | $1,578 |
| Travoprost | 13 | $1,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $714 | $75,161136 claims |
| Bausch & Lomb Americas Inc.Xiidra | $6,209 | $13,81915 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $148 | $2,34213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Hattiesburg
- Adam QuinnHattiesburg$29K
- Jaime JimenezHattiesburg$13K
- Wade TuckerHattiesburg$4K
- Stoney WilliamsonHattiesburg$3K
- Charles RichardsonHattiesburg$3K
- Todd WilliamsonHattiesburg$3K
- Benjamin PaceHattiesburg$3K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.